We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.
- Authors
Swartz, Adam M.; Congdon, Kendra L.; Nair, Smita K.; Li, Qi-Jing; Herndon II, James E.; Suryadevara, Carter M.; Riccione, Katherine A.; Archer, Gary E.; Norberg, Pamela K.; Sanchez-Perez, Luis A.; Sampson, John H.
- Abstract
Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers express a low number of neoantigens; in these cases, ensuring the immunotherapeutic potential of each neoantigen-derived epitope (neoepitope) is crucial. In this study, we discovered that therapeutic vaccines targeting immunodominant major histocompatibility complex (MHC) I-restricted neoepitopes require a conjoined helper epitope in order to induce a cytotoxic, neoepitope-specific CD8+ T-cell response. Furthermore, we show that the universally immunogenic helper epitope P30 can fulfill this requisite helper function. Remarkably, conjoined P30 was able to unveil immune and antitumor responses to subdominant MHC I-restricted neoepitopes that were, otherwise, poorly immunogenic. Together, these data provide key insights into effective neoantigen vaccine design and demonstrate a translatable strategy using a universal helper epitope that can improve therapeutic responses to MHC I-restricted neoepitopes.
- Subjects
MAJOR histocompatibility complex; SPOROZOITES; IMMUNE response; BACTEREMIA; GLYCOLYSIS
- Publication
NPJ Vaccines, 2021, Vol 6, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-020-00273-5